Notice Number: NOT-MH-05-017
Release Date: September 12, 2005
National Institute of Mental Health (NIMH), (http://www.nimh.nih.gov/)
The objective of PAR-05-010 (http://grants.nih.gov/grants/guide/pa-files/PAR-05-010.html) is to “establish CDDGs to conduct innovative, high impact clinical research focused on the clinical development of IND-ready pharmacological agents targeting novel molecular targets implicated in the pathophysiology of mental illness.” To date, applications submitted in response to this announcement have proposed the development of pharmacological agents that are at a very wide range of “IND-readiness.” In order to standardize review criteria and streamline the award process, the NIMH will now require all applicants to PAR-05-010 to certify within their grant submission that an Investigational New Drug application for the relevant compound has been filed with the FDA and provide the date of the filing. In addition, applicants should be aware that funding to any successful application will be restricted until final IND approval has been obtained from the FDA.
Inquiries regarding this Notice may be directed to:Wayne S. Fenton, M.D.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)